Inozyme Pharma

United States · Research

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare diseases that impact bone health, blood vessel function, and soft tissue mineralization. The company focuses on the PPi-Adenosine Pathway, which plays a vital role in maintaining skeletal and vascular health. Inozyme aims to address conditions with high unmet medical needs, translating scientific insights into effective treatments. The company's lead product, INZ-701, is an investigational enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. This therapy targets diseases such as ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, which are associated with severe mineralization disorders. Inozyme collaborates with clinicians, researchers, and patient advocacy groups to enhance treatment access and support clinical trial participation, emphasizing a patient-centric approach in its development process.